Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Therapies for Moderate to Severe Crohn’s Disease
2024-513009-30-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 32
01
Overview
Phase 2, randomised trial of vedolizumab, risankizumab, ABBV-8736, lutikizumab, ABBV-382 and 1 more in Crohn's disease (7 arms), sponsored by AbbVie Inc. Primary endpoint: Endoscopic remission at Week 12. Planned start Nov 2024; status: authorised.
02
Drugs
vedolizumabrisankizumabABBV-8736lutikizumabABBV-382
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-513009-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513009-30-00.